Mizuguchi Yoshiaki, Yokomuro Shigeki, Mishima Takuya, Arima Yasuo, Shimizu Tetsuya, Kawahigashi Yutaka, Kanda Tomohiro, Yoshida Hiroshi, Takizawa Toshihiro, Tajiri Takashi
Department of Surgery for Organ Function and Biological Regulation, Nippon Medical School, Tokyo, Japan.
Gastroenterology. 2005 Nov;129(5):1654-62. doi: 10.1053/j.gastro.2005.08.013.
BACKGROUND & AIMS: Transforming growth factor beta (TGF-beta) receptor II (TGF-betaRII), which is essential for TGF-beta signaling and is involved in the causation or participates in the pathway of various human disorders, is consequently considered a key target for therapeutics and analysis of the pathophysiology associated with disruption of the TGF-beta system. In the liver, TGF-beta plays an essential role in hepatocyte apoptosis, growth inhibition, and progression of fibrogenesis. There is a critical need to introduce technology involving the TGF-beta system, such as RNA interference (RNAi), which has high potential for in vivo therapeutics and analytical activities.
Here, we investigated the effect of short hairpin RNA targeting TGF-betaRII, using hepatocyte injury in human and mouse cell lines and liver injury mouse models.
We demonstrated that short hairpin RNA targeting TGF-betaRII can be used to silence TGF-betaRII genes in mouse and human cell lines, and physiologic and morphologic changes in hepatocytes suffering from acute injury are spared by RNAi-mediated gene silencing of the target gene and by suppressing downstream signal transduction. Furthermore, short hairpin RNA targeting TGF-betaRII protected mice from life-threatening acute liver failure.
Our study suggests the potential use of TGF-betaRII silencing by RNAi as an analytical tool for TGF-beta signaling and gene-specific therapy in human disorders.